Abstract

This article explores the intricate molecular ballet of enzyme induction and inhibition in the realm of therapeutics. Enzymes, particularly those of the cytochrome P450 family, play a pivotal role in drug metabolism, and their modulation can significantly impact the pharmacokinetics and pharmacodynamics of various medications. Enzyme induction involves the upregulation of specific enzymes, influencing drug metabolism, while enzyme inhibition restrains these molecular performers, altering the fate of co-administered drugs. The article delves into the nuances of this balletic interplay, emphasizing its implications in drug development, clinical practice, and the challenges posed by individual variability and pharmacogenomics